$0.46
4.14%
Nasdaq, Fri, Dec 27 2024
ISIN
US8177631053
Symbol
SESN
Sector
Industry

Sesen Bio, Inc. Stock price

$0.46
-0.38 45.27% 1M
-0.82 64.04% 6M
-2.47 84.29% YTD
-2.62 85.06% 1Y
-1.07 69.94% 3Y
-1.29 73.73% 5Y
-20.24 97.78% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.02 4.14%
ISIN
US8177631053
Symbol
SESN
Sector
Industry

Key metrics

Market capitalization $19.22m
Enterprise Value $-4.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.06
EV/Sales (TTM) EV/Sales -0.21
P/S ratio (TTM) P/S ratio 0.95
P/B ratio (TTM) P/B ratio negative
Dividend yield 0.00%
Last dividend (FY23) $5.15
Revenue growth (TTM) Revenue growth 90.67%
Revenue (TTM) Revenue $20.27m
EBIT (operating result TTM) EBIT $-66.77m
Free Cash Flow (TTM) Free Cash Flow $-68.49m
Cash position $26.88m
EPS (TTM) EPS $-1.56
P/E forward negative
P/S forward 0.90
EV/Sales forward negative
Short interest 1.05%
Show more

Is Sesen Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Sesen Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Sesen Bio, Inc. forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Sesen Bio, Inc. forecast:

Buy
20%
Hold
80%

Financial data from Sesen Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
20 20
91% 91%
100%
- Direct Costs 4.77 4.77
125% 125%
24%
16 16
82% 82%
76%
- Selling and Administrative Expenses 14 14
44% 44%
69%
- Research and Development Expense 64 64
14% 14%
313%
-62 -62
14% 14%
-306%
- Depreciation and Amortization 4.77 4.77
125% 125%
24%
EBIT (Operating Income) EBIT -67 -67
10% 10%
-329%
Net Profit -64 -64
13% 13%
-315%

In millions USD.

Don't miss a Thing! We will send you all news about Sesen Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Head office United States
CEO Steven Kelly
Employees 107
Founded 2016
Website carismatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today